Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP

Panelists discuss how molecular testing and liquid biopsies are crucial for tracking estrogen receptor 1 (ESR1) mutations in patients with metastatic breast cancer, particularly as a mechanism of resistance to aromatase inhibitor treatment.